Author:
Rogojina Anna,Gajewski Stefan,Bahmed Karim,Osheroff Neil,Nitiss John L.
Reference169 articles.
1. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH (1998) Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4(3): 683–691
2. Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR (2010) Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 34(4): 487–491
3. Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM (2007) A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 25(2): 147–154
4. Aoyagi Y, Kobunai T, Utsugi T, Oh-hara T, Yamada Y (1999) In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Jpn J Cancer Res 90(5): 578–587
5. Arlin ZA (1989) Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Bone Marrow Transplant 4 Suppl 1: 57–59
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献